In order to investigate the effects of mecobalamin on experimental carcinomatous neuropathy, hepatoma-bearing rats were produced by chronic feeding of 3'-methyl 4-dimethylaminoazobenzene (3'-Me-DAB), and neuropathy was quantitatively evaluated by the motor nerve conduction velocity (MCV) of the dorsal nerve trunks.
The rats were kept feeding on Oriiental Solid Food containing 0.06% 3'-Me-DAB until 12 weeks after the start of the experiment when hepatoma was confirmed to develop and 500μg of mecobalamin injection was initiated twice a week. At 17 and 23 weeks with an interval of 2 weeks after the last injection, MCV and serum B
12 level were measured. The MCV's of vitamin B
12-treated hepatoma rats were not reduced at 17 weeks as compared with untreated hepatoma-bearing rats although in the later stage the difference between the two groups was not remarkable. It was quite reasonable that the serum vitamin B
12 levels were low in the control hepatoma rats while those of vitamin B
12-treated hepatoma rats were high. However, interesting enough, a positive correlation was observed between MCV and serum vitamin B
12 level in the control hepatoma rats.
From the above results, it was suggested that vitamin B
12 deficiency may at least one of the causes of neuropathy in hepatoma-bearing rats, and vitamin B
12 administration could prevent carcinomatous neuropathy.
View full abstract